ATRX guards against aberrant differentiation in mesenchymal progenitor cells
Fang Yan(Memorial Sloan Kettering Cancer Center), Benjamin A. Nacev(University of Pittsburgh), William D. Tap(Memorial Sloan Kettering Cancer Center), Thomas S. Carroll(King's College London), S. J. Singer(Memorial Sloan Kettering Cancer Center), Yakshi Dabas(Rockefeller University), Douglas Barrows(Rockefeller University)
Cited by 11
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|733
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
|The Lancet|2019|472
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
|Nature Communications|2022|219